Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
Immune checkpoint blockade (ICB) has revolutionized modern cancer therapy, arousing
great interest in the neuro-oncology community. While several reports show that subsets of …
great interest in the neuro-oncology community. While several reports show that subsets of …
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
S Liu, Q Sun, X Ren - Journal of Hematology & Oncology, 2023 - Springer
The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …
especially the application of immune checkpoint inhibitors in clinical practice. Although …
Glioma progression is shaped by genetic evolution and microenvironment interactions
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma
Only a subset of recurrent glioblastoma (rGBM) responds to anti-PD-1 immunotherapy.
Previously, we reported enrichment of BRAF/PTPN11 mutations in 30% of rGBM that …
Previously, we reported enrichment of BRAF/PTPN11 mutations in 30% of rGBM that …
Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas
J Bao, W Lu, H Duan, Y Ye, J Li, W Liao, Y Li… - Frontiers in …, 2022 - frontiersin.org
Background Cuproptosis is a newly discovered unique non-apoptotic programmed cell
death distinguished from known death mechanisms like ferroptosis, pyroptosis, and …
death distinguished from known death mechanisms like ferroptosis, pyroptosis, and …
Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications
CNS immune defenses are marshaled and dominated by brain resident macrophages and
microglia, which are the innate immune sentinels and frontline host immune barriers against …
microglia, which are the innate immune sentinels and frontline host immune barriers against …
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
D Kreatsoulas, C Bolyard, BX Wu, H Cam… - Journal of Hematology & …, 2022 - Springer
Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …
Anti–PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells
Purpose: Anti-programmed cell death protein 1 (PD-1) therapy has demonstrated
inconsistent therapeutic results in patients with glioblastoma (GBM) including those with …
inconsistent therapeutic results in patients with glioblastoma (GBM) including those with …
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
B Segura-Collar, S Hiller-Vallina, O de Dios… - Acta neuropathologica …, 2023 - Springer
Glial-origin brain tumors, including glioblastomas (GBM), have one of the worst prognoses
due to their rapid and fatal progression. From an oncological point of view, advances in …
due to their rapid and fatal progression. From an oncological point of view, advances in …
ERK1/2 phosphorylation predicts survival in recurrent glioblastoma following intracerebral and adjuvant PD-1/CTLA-4 immunotherapy: A REMARK-guided analysis
Purpose: Evidence suggests that MAPK pathway activation, as measured by ERK1/2
phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent …
phosphorylation (p-ERK), predicts overall survival (OS) in patients with recurrent …